A PYXAX editorial reference. Source review: October 20, 2026.
A country label, a laboratory result and a manufacturing record can each contain useful information. They answer different questions. Calling any one of them a complete definition of peptide quality makes the evidence do more work than it can support.
The first question is therefore practical: which claim are we trying to check? A statement about molecular identity needs evidence about identity. A statement about manufacturing control needs evidence about the manufacturing system. A national statistic cannot supply either for an individual lot.
What the overseas-facility figure actually counts
In a May 16, 2025 speech, FDA official Grace Graham said 73% of FDA-registered active-pharmaceutical-ingredient manufacturing facilities were outside the United States. The unit is registered facilities. It is not the proportion of every medicine’s ingredients, a list of one company’s suppliers or a result for any research sample. FDA speech.
Using that figure to infer that two suppliers offer equivalent material would require evidence the statistic does not contain. The same applies in reverse: location alone cannot determine a particular lot’s analytical results.
Manufacturing oversight extends beyond a finished-sample test
FDA describes current good manufacturing practice as a system for designing, monitoring and controlling pharmaceutical manufacturing. Its explanation includes process controls, facilities, records and investigations; it explicitly explains why testing alone is insufficient. A single analytical certificate should not be presented as equivalent to that system. FDA CGMP explanation.
That distinction does not make a laboratory measurement unimportant. It defines the scope of the claim supported by it.
Read a lot record one question at a time
For a research record, keep these fields separate:
| Question | Evidence to inspect | Inference to avoid |
|---|---|---|
| Which sample was examined? | Sample identifier, lot mapping and report date | Assuming a certificate applies to every later lot |
| What was measured? | Named method, reported result and its basis | Treating a chromatographic percentage as a complete material specification |
| What remains outside the record? | Unperformed tests, stated limitations and missing documentation | Treating an omitted result as a passing result |
| What manufacturing claim is being made? | Records that address the manufacturing system | Substituting a sample result for system-wide evidence |
This is an interpretation framework, not an audit of a named supplier. For the analytical distinctions, use the existing purity and identity reference. For report-to-lot matching, use the COA interpretation guide.
The useful conclusion is bounded: define the claim, inspect evidence that addresses it, and preserve the limits. Neither a familiar name nor a certificate eliminates that work.
PYXAX’s verification scope
PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.
The verification panel concerns the batch record. It does not supply regulatory authorization, characterize another supplier’s material or establish suitability for human use.
All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.